Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer's disease: a qualitative interview study.

Trials·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug.

Alzheimer's & dementia (New York, N. Y.)·2025
Same author

Astrocytes provide a unique biomarker for Alzheimer's and other pathologies.

The journal of prevention of Alzheimer's disease·2025

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Todd Feaster1, Prajakta Dinesh Mangeshkar2, Siew Tin Gan2

  • 1Acumen Pharmaceuticals, Inc, Newton, MA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括

血pTau217查有效地识别了阿尔茨海默病 (AD) 试验的参与者,降低了成本和参与者负担. 这种方法通过选择具有粉样蛋白病理的个体来提高试验效率.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

科学领域:

  • 神经学和临床试验研究
  • 生物标志物发现和验证

背景情况:

  • 阿尔茨海默病 (AD) 临床试验经常排除缺乏粉样蛋白病理的个体,导致高屏幕失败率.
  • 之前的研究,如INTERCEPT-AD,显示由于负粉样质子辐射断层扫描 (PET) 扫描导致显著的屏幕故障.
  • 血pTau217度是高度预测阿尔茨海默病理的,提供了一个潜在的查工具.

研究的目的:

  • 在ALTITUDE-AD研究中评估血pTau217测量的实用性,以丰富参与者在早期AD试验中具有足够的粉样蛋白负担.
  • 评估pTau217查对降低与确认性粉样蛋白PET或脑脊液 (CSF) 测试相关的成本和参与者负担的影响.

主要方法:

  • 高度AD (NCT06335173) 是一项2期研究,涉及患有早期AD和粉样蛋白病理的个体.
  • 在北美地区的查包括一个两部分的过程:血pTau217测试 (Fujirebio Lumipulse测试),然后对那些pTau217 ≥0.15 pg/mL的人进行确认性粉样蛋白PET或CSF Aβ42/40测试.
  • 成本分析将两部分选策略与未使用pTau217的预计成本进行了比较.

主要成果:

  • 48%的查参与者血pTau217 ≥0.15 pg/mL,符合确认测试的条件.
  • 81%的pTau217升高的参与者通过PET或CSF满足了粉样蛋白的资格标准.
  • 该pTau217查策略在美国和加拿大地点减少了大约1000万美元 (40%) 的总查成本.

结论:

  • 血pTau217查有效丰富了早期AD临床试验的参与者满足基于粉样蛋白的纳入标准.
  • 这种方法显著降低了查成本,并最大限度地减少了潜在参与者的侵入性手术,如腰部穿刺和PET扫描中的辐射暴露.